|Bid||0.00 x 1000|
|Ask||0.00 x 1300|
|Day's Range||67.86 - 69.94|
|52 Week Range||36.92 - 74.00|
|Beta (3Y Monthly)||1.97|
|PE Ratio (TTM)||60.60|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
ANI (ANIP) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk […]
On a per-share basis, the Baudette, Minnesota-based company said it had net income of 4 cents. Earnings, adjusted for non-recurring costs, came to $1.30 per share. The drugmaker posted revenue of $52.9 ...
ANI Pharmaceuticals (ANIP) closed at $70.24 in the latest trading session, marking a -1.04% move from the prior day.
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company that is really flourishing, you can make more than 100%. For instance, the price of ANI Pharmaceuticals...
The Medicines Company (MDCO) suffers narrower-than-expected loss in Q1. The company progresses well with its sole pipeline candidate, inclisiran.
Zacks.com featured expert Kevin Matras highlights: Advanced Emissions Solutions, Verint Systems, Great Lakes Dredge & Dock, ANI Pharmaceuticals and ACI Worldwide
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $68.88, marking a -0.17% move from the previous day.
Ultragenyx???s (RARE) UX007 receives Fast Track designation and Rare Pediatric Disease designation by the FDA for the treatment of long-chain fatty acid oxidation disorders.
In the latest trading session, ANI Pharmaceuticals (ANIP) closed at $69.44, marking a +1.71% move from the previous day.
Cash gives a company vitality and strength. It holds the key to its existence, development and success, and can indeed be referred to as its lifeblood.
Zacks.com featured expert Kevin Matras highlights: Herc, ANI Pharmaceuticals, Kamada, SP Plus and SkyWest
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.